http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101814048-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54 |
| filingDate | 2014-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101814048-B1 |
| titleOfInvention | Thrombopoietin developed with mass production for oral dosage and mass production process therof |
| abstract | The present invention relates to an improved orally administered thrombopoietin and a mass production process thereof, which are improved to enable mass production, which is indispensably required in the development of a medicament for oral administration, Protease Resistance Improved Trombopoietin was successfully fused to ubiquitin and hysterin in the form of insoluble anti-foam, and purified using a purification process using a hydration process, fusion partner removal process, ligand affinity chromatography, ion exchange chromatography The process was successful in obtaining a large amount in a high purity active form. |
| priorityDate | 2014-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 216.